HEALTHCARE FINANCE

Doing Well, While Doing Good

CVC Marathon is a distinguished healthcare partner offering strategic capital solutions to biopharma, diagnostic, medical device, and service-oriented companies.

CVC Marathon has invested over $5 billion in capital for healthcare, covering both public and private debt, royalties, and equity.

Our competitive edge stems from our team's rigorous scientific analysis and financial underwriting across:

01.

Pharma

02.

Biotech

03.

Medical Devices

04.

Services

05.

Managed Care

06.

Hospital Systems

$9B+

Invested in the healthcare industry

350M+

Patients addressed globally by companies that CVC Marathon financed

25+

Years Of average experience for Healthcare Finance

CVC Marathon has been committed to advancing patient health, while adhering to our guiding principle of "Doing Well, While Doing Good," through the delivery of customized solutions for our partners.

CVC Marathon is comprised of a diverse group of experts, including:

  • Dedicated Investment Professionals
  • Healthcare Bankers
  • PhDs and MDs
  • 6 Renowned Leaders on Medical Advisory Board
  • Consultants
  • Renowned Medical Advisory Board

CVC Marathon works collaboratively in striving to achieve optimal outcomes for our partners. Our expertise in navigating numerous market cycles and our ability to identify, price, and structure investments allow us to make thoughtful decisions across the capital structure. We strive to consistently deliver exceptional performance through superior sourcing, rigorous medical research, fundamental financial analysis, execution, and robust internal asset management.

video image

Investment
Strategies

Royalty Monetization & Asset-Based Lending

Generates consistent cash flow with limited correlation to major asset classes and senior-secured, downside protection.

  • Asset-Based Secured Loans
  • Royalty Acquisitions
  • Synthetic Royalty

Capital Solutions

Provides attractive total return across a multi-strategy credit platform.

  • Senior Loans
  • Mezzanine Debt
  • Convertible Debt
  • Preferred Equity
  • Customized Capital Solutions

Select CVC Marathon
Transactions

CVC Marathon is focused on providing non-dilutive, structured solutions to healthcare companies to fund product launches, acquire assets, license products, or re-invest capital in earlier-stage R&D Projects.

  • Kaleo Pharmaceuticals
  • Dermavant
  • Healogics
  • ATI Physical Therapy
  • Team Health
  • Kynmobi

Investment Vehicles

  • Closed-End Funds
  • Fund of One & Separately Managed Accounts

CVC Marathon's world-class and exclusive Medical Advisory Board of 6 renowned thought-leaders are active across premier academic institutions, biopharma and pharmaceutical companies.

CVC Marathon's Healthcare Team has a successful history of partnering with inventors, educational institutions, hospitals, universities, and pharmaceutical companies. Under the leadership of Dr. Evan Bedil, CVC Marathon's 15-person team includes 9 in-house healthcare professionals in the U.S. and Europe with diverse skills including scientific, clinical, commercial, financial, operational, and legal expertise.

Contact Us

To contact CVC Marathon's Healthcare Finance team, please reach out to one of the key contacts below:

For Healthcare Transactions:

Dr. Evan Bedil
Managing Director - Healthcare Finance
ebedil@marathonfund.com

For Investors:

Jason Friedman
Partner - Global Head of Strategy and
Business Development
jfriedman@marathonfund.com or
investors@marathonfund.com

You are now leaving Marathon Asset Management's website. By clicking the Learn More button, you will be connected to a website maintained by John Hancock Investment Management Distributors LLC, and you acknowledge and agree to the following:

We are providing a link to a third-party website solely as a convenience to you, as this website may provide useful content. We do not control the content on the third-party website, do not guarantee any claims made on it, and do not endorse the website, its sponsor, or any of the content, policies, activities, products, or services offered on the website or by any advertiser on the website. We disclaim any responsibility for the website's performance or interaction with your computer, its security and privacy policies and practices, and any consequences that may result from visiting the website. The link is not intended to create an offer to sell, or a solicitation of an offer to buy or hold, any securities.

About the Fund

John Hancock Asset-Based Lending Fund is a Massachusetts business trust that is registered under the Investment Company Act of 1940, as amended, as a continuously offered, non-diversified, closed-end management investment company.

 

Fund shares are illiquid and, therefore, an investment in the fund should be considered a speculative investment that entails substantial risks. Investors could lose all or substantially all of their investment. Shares of the fund are not listed on any securities exchange, and it is not anticipated that a secondary market for the fund's shares will develop; therefore, an investment in the fund may not be suitable for investors who may need the money they invest in a specified timeframe. Please see the fund's prospectus for additional risks. Request a prospectus from your financial professional, by visiting jhinvestments.com, or by calling us at 800-225-5291. The prospectus includes investment objectives, risks, fees, expenses, and other information that you should consider carefully before investing.

John Hancock Investment Management Distributors LLC, Member FINRA, SIPC, 200 Berkeley Street, Boston, MA 02116, 800-225-5291, jhinvestments.com

You are now leaving Marathon Asset Management's website. By clicking the Learn More button, you will be connected to a website maintained by John Hancock Investment Management Distributors LLC, and you acknowledge and agree to the following:

We are providing a link to a third-party website solely as a convenience to you, as this website may provide useful content. We do not control the content on the third-party website, do not guarantee any claims made on it, and do not endorse the website, its sponsor, or any of the content, policies, activities, products, or services offered on the website or by any advertiser on the website. We disclaim any responsibility for the website's performance or interaction with your computer, its security and privacy policies and practices, and any consequences that may result from visiting the website. The link is not intended to create an offer to sell, or a solicitation of an offer to buy or hold, any securities.

About the Fund

The John Hancock High Yield ETF is an exchange traded fund that is registered under the Investment Company Act of 1940, as amended. The John Hancock High Yield ETF, driven by a consistent portfolio construction process and diversified approach, aims to deliver strong category returns with index-like risk.

 

ETF shares are bought and sold through exchange trading at market price (not NAV) and are not individually redeemed from the fund. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns. Please see the fund's prospectus for additional risks. Request a prospectus from your financial professional, by visiting jhinvestments.com, or by calling 800-225-5291. The prospectus includes investment objectives, risks, fees, expenses, and other information that you should consider carefully before investing.

John Hancock Investment Management Distributors LLC, Member FINRA, SIPC, 200 Berkeley Street, Boston, MA 02116, 800-225-5291, jhinvestments.com